Top Stories

ORLANDO (March 10, 2018) – The ODYSSEY OUTCOMES trial results, announced today at the American College of Cardiology 67th Annual Scientific Sessions in Orlando, revealed the addition of alirocumab to maximally tolerated statin significantly reduced major adverse cardiovascular events (MACE) compared to those on maximally tolerated statin and placebo. 

JACKSONVILLE, Fla. -- The National Lipid Association announced Monday it has united with MD Magazine®, a leading online and print source of physician news, conference coverage, and peer-to-peer discussion, through Michael J. Hennessy Associates' Strategic Alliance Partnership (SAP) Program. The partnership will also include sister publications, Rare Disease Report® and Pharmacy Times®.

The Journal of Clinical Lipidology announced on Monday its 2016 Impact Factor has risen to 5.812, up from 4.906 in 2015. Led by Editor-In-Chief W. Virgil Brown, M.D., the JCL has seen a steady growth in submissions and readership since first publishing in 2007. It now ranks 17th of 256 journals in its category (pharmacology and pharmacy).